Authors:
W.W.I.S. Rodrigo, D. C. Alcena, Z. Kou, T. J. Kochel, K. R. Porter, G. Comach, R. C. Rose, X. Jin, and J. J. Schlesinger
Summary:
Sera from patients involved in a Peruvian outbreak of dengue virus serotype 1 infection cross-neutralized the American genotype of dengue virus serotype 2 up to 100-fold more efficiently than they did the virulent Asian genotype of dengue virus serotype 2, as determined by a plaque reduction neutralization test (PRNT) with CV-1 fibroblasts modified to express human FcY receptor CD32. The concordant preferential immune enhancement of the Asian genotype of dengue virus serotype 2 in human monocytes suggests that such a modification might strengthen the correlation between the PRNT titer and protection.
Source:
Clinical & Vaccine Immunology; Vol. 16, No. 2, 285-287 (02/09)